This page shows the latest NPS news and features for those working in and with pharma, biotech and healthcare.
The use of Fectroja in a range of infections is supported by data from three clinical studies, APEKS-cUTI, APEKS-NP, and CREDIBLE-CR.
This included nosocomial pneumonia (NP), bloodstream infections (BSI), sepsis and complicated urinary tract infections (cUTI). ... The APEKS-NP study evaluated Fetcroja in severely ill patients with hospital-acquired, ventilator-associated or
The use of Fectroja in a range of infections is supported by data from three clinical studies, APEKS-cUTI, APEKS-NP, and CREDIBLE-CR.
The lead NASH candidate at that time was NP 201, but seems to have been leapfrogged by NGM313, now renamed MK-3655.
Two proteins (NP-C1 and NP-C2) help control lipid transport within cells in patients with this disorder, with the majority (95%) of cases involving mutations in the NP-C1 gene.
Natpar was one of the primary reasons Shire forked out $5.2bn to buy NPS Pharma in 2015 just before the FDA gave its go-ahead for the new therapy, which
More from news
Approximately 3 fully matching, plus 20 partially matching documents found.
Interestingly, across all the countries mentioned above there has been no drop-off in the positive NPS for F2F, despite much lower activity and increased use of other channels. ... Germany also has a stable positive NPS at 35% and has seen F2F visits
As many of the safety and manufacturing issues surrounding our MVA-NP M1 vaccine are already de-risked, a positive efficacy readout in the challenge study should allow us to take
So bad in fact, that the best Net Promoter Score (NPS) is a whopping -40% (minus!).
$6bn deal that was completed in January 2016. Before that the firm had a busy 2015, buying US rare disease-focused biotech NPS Pharma for $5.2bn and rare disease and
NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn. ... Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America
He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck &Co.
He joins from NPS Pharmaceuticals where he was VP finance. US-based electroceutical healthcare company electroCore has named Patrick Fabbio as chief financial officer. ... Fabbio has over 20 years of financial leadership experience in public and private
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...